Compare Hims and Hers Health Inc (HIMS) vs HubSpot Inc (HUBS) Price & Performance

HIMS stock trades at $30.00, down 5.57% amid mixed Q2 2026 results. Revenue growth remains strong, with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a wider-than-expected quarterly loss. Technical indicators are neutral to bearish, with the price near key support at $30. Recent news highlights an FTC investigation and class-action lawsuits as headwinds.

The investment outlook is cautious. Growth prospects from subscriber gains and AI integration are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33.00 price target, suggesting limited near-term upside amid profitability concerns and negative free cash flow trends.

HubSpot (HUBS) trades at $210.92, down 2.31% on the day, amid a bearish technical signal and recent stock volatility following Q2 2026 results. The company reported strong earnings beats but lowered its customer-growth forecast, contributing to a sharp price decline from previous highs. Revenue growth remains robust at 20% year-over-year, yet high valuation multiples and margin pressures present challenges. Analyst sentiment is predominantly bullish with a $233.93 consensus target, but near-term execution risks and increased AI spending weigh on investor confidence.

The outlook for HUBS hinges on successful execution of its AI-driven strategy amid slower customer acquisition. Investment opportunity lies in its solid revenue growth and market position if it can navigate budget scrutiny and competitive pressures. Key risks include heightened execution risks, potential securities litigation, and the financial impact of strategic shifts, which could limit near-term upside despite long-term transformation potential.